EMA — authorised 10 February 1997
- Application: EMEA/H/C/000129
- Marketing authorisation holder: GlaxoSmithKline Biologicals S.A.
- Local brand name: Twinrix Paediatric
- Indication: Twinrix Paediatric is indicated for use in non-immune infants, children and adolescents from one year up to and including 15 years who are at risk of both hepatitis-A and hepatitis-B infection.
- Status: approved